Regeneron Pharmaceuticals
No price chart data available for 1D timeframe.
Rating
Why Price Moved
Shares are trading higher after positive CIDEB siR...
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of ill...
Latest News
8 hours ago · fxempire.com
REGN Price Forecast: Rally Faces Resistance After 37% AdvanceRegeneron shares face growing resistance after a 37% advance, with potential correction targets emerging while the intermediate- and long-term bullish trends remain intact.
2 days ago · fool.com
Regeneron Has $16 Billion in Net Cash and Trades Near 20 Times Earnings. Is It the Cheapest Big Biotech?Regeneron sells 16 products, and they have helped revenue climb in recent years. The company's leading products delivered record revenue in the third quarter.
4 days ago · globenewswire.com
POTS Phase 2 Trial Shows Baloncibart, a First-in-Class NPR1 Blocking Antibody, Reduced Orthostatic Heart Rate and Improved Orthostatic SymptomsData presented today for the first time at the American Autonomic Society (AAS) annual meeting POTS (postural orthostatic tachycardia syndrome) is a debilitating condition characterized by a marked increase in heart rate upon standing and associated orthostatic symptoms, with no FDA-approved treatments available A single dose of baloncibart reduced the exaggerated heart rate response to standing and improved orthostatic symptoms through four weeks; biomarker changes were consistent with plasma volume expansion, the intended effect of NPR1 blockade Potentially pivotal Phase 3 trial planned for first half of 2027 TARRYTOWN, N.Y., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced results from the Phase 2 PINNACLE trial in adults with postural orthostatic tachycardia syndrome (POTS) evaluating baloncibart, a novel, investigational, first-in-class monoclonal antibody that blocks natriuretic peptide receptor 1 (NPR1).
4 days ago · zacks.com
REGN Soars 27.4% in a Month: Buy, Sell or Hold the Stock?Regeneron's strong Eylea HD and Dupixent sales, expanding oncology portfolio and promising pipeline fuel growth prospects as Eylea faces intensifying competition.
5 days ago · zacks.com
Why Regeneron (REGN) is a Top Value Stock for the Long-TermThe Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
6 days ago · seekingalpha.com
Regeneron Pharmaceuticals, Inc. (REGN) Discusses Genetic Center and CIDEB siRNA Development for MASH TranscriptRegeneron Pharmaceuticals, Inc. (REGN) Discusses Genetic Center and CIDEB siRNA Development for MASH Transcript
6 days ago · marketbeat.com
Regeneron Pharmaceuticals Advances Liver Drug After Early Trial Cuts Liver Fat by Up to 80%Regeneron Pharmaceuticals NASDAQ: REGN is advancing its experimental CIDEB therapy into later-stage studies for a form of liver disease after an early trial showed a single dose substantially reduced liver fat, executives said during an investor event.
8 days ago · globenewswire.com
CIDEB siRNA Normalizes Liver Fat and Improves Liver Injury Markers in MASLD Patients, as Highlighted at AASLDSingle administration of CIDEB siRNA resulted in rapid, deep and durable reductions in liver fat by up to 80% that were sustained through 36 weeks
13 days ago · zacks.com
Why Regeneron (REGN) Might be Well Poised for a SurgeRegeneron (REGN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
13 days ago · zacks.com
REGN vs. ILMN: Which Stock Is the Better Value Option?Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Regeneron (REGN) and Illumina (ILMN). But which of these two stocks presents investors with the better value opportunity right now?
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove REGN